title: The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.
abstract: A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdetection of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances.
authors.affiliation: From the Department of Urology, UC San Diego Health System, La Jolla, California.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: McDonald
authors.affiliation: From the Department of Urology, UC San Diego Health System, La Jolla, California.
authors.forename: J Kellogg
authors.initials: JK
authors.lastname: Parsons
mesh_terms: D000367:Age Factors; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D003657:Decision Making; D051517:Digital Rectal Examination; D055088:Early Detection of Cancer / Q000379:methods; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening / Q000379:methods; D011159:Population Surveillance; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology*; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor